NCT07348055RecruitingPhase 1/2
A Study of GR1803 in Systemic Lupus Erythematosus
A Phase Ib/IIa Clinical Trial Evaluating the Safety, Tolerability, and Efficacy of GR1803 Injection in Subjects With Systemic Lupus Erythematosus
Source: ClinicalTrials.gov · Last updated 10 Mar 2026
Brief summary (registry, in English)
to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- First submitted
- 25 Dec 2025
- Start date
- 2 Feb 2026
- Primary completion date
- 1 Jun 2027
- Lead sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Diseases
- Lupus (SLE)
- NCT number
- NCT07348055
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 44
- From 2 Feb 2026 to the primary completion date, 1 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- with unstable acute and chronic diseases
- active infection
- history of malignant tumor within 5 years
Who the study is looking for
- comfirmed diagnosis of systemic lupus erythematosus
- SLEDAI-2K≥6分
- written informed consent and ability to comply with protocol requirements
- have received adequate dose of glucocorticoids, antimalarials, immunosuppressants for 3 months
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Coordinator of this site? Confirm its status | Wuhan | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.